OCS (Oculis Holding AG) Land And Improvements : $0.00 Mil (As of Sep. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Oculis Holding AG Land And Improvements?

Oculis Holding AG's land and improvements for the quarter that ended in Sep. 2024 was $0.00 Mil.

Oculis Holding AG Land And Improvements Historical Data

The historical data trend for Oculis Holding AG's Land And Improvements can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oculis Holding AG Land And Improvements Chart

Oculis Holding AG Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Land And Improvements

Oculis Holding AG Quarterly Data
	Dec20	Jun21	Sep21	Dec21	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Land And Improvements	Get a 7-Day Free Trial									-	-	-	-	-

Oculis Holding AG Land And Improvements Calculation

Land is the surface or crust of the earth, which can be used to support structures, and may be used to grow crops, grass, shrubs, and trees. Land is characterized as having an unlimited life (indefinite). Land improvement is a long-term asset which indicates the cost of the constructed improvements to land, such as driveways, walkways, lighting, and parking lots.

Oculis Holding AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oculis Holding AG (NAS:OCS) » Definitions » Land And Improvements

Comparable Companies

Traded in Other Exchanges

OCS:Iceland CR5:Germany

Address

Bahnhofstrasse 7, Zug, CHE, 6300

Website

https://www.oculis.com

Oculis Holding AG is a global biopharmaceutical company purposefully driven to save sight and improve eye care. It includes OCS-01, a topical retinal candidate for diabetic macular edema (DME); OCS-02, a topical biologic candidate for dry eye disease (DED); and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophtha disorders such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis.